Get HBV Advocate’s Christine Kukka’s take on the top HBV related, published reports from the AASLD Liver Meeting as she provides her Top Ten List!
Top Ten Reports from the 65th Annual Liver Meeting
By Christine M. Kukka, HBV Advocate
Hepatitis B experts from around the world met at the 65th annual American Association for the Study of Liver Diseases (AASLD) conference in Washington D.C. this week to share the latest in hepatitis B treatment and research.
- Which combination of antivirals and interferon works best against hepatitis B
- Tenofovir continues to excel with no signs of drug resistance after eight years
- Tenofovir treatment is safe over an entire pregnancy for both mother and child
- Tenofovir and entecavir combination successful against drug-resistant HBV
- Who remains at risk for hepatitis B in the U.S.?
- Antivirals appear to lower liver cancer risk
- But antivirals don’t reduce cancer risk in older patients with cirrhosis
- How long do patients have to keep taking antivirals after they lose HBeAg and achieve undetectable viral load?
- Liver cancer risk remains, even after HBsAg clearance in older, male patients
- Experts say treatment is needed when ALT levels are only moderately elevated
Continue reading "AASLD 2014 Liver Meeting – HBV Coverage"